Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2005

View Archived Issues

Isotechnika sees progress on multiple fronts

MSA proves to be beneficial for the treatment of lymphomas

Vildagliptin safely lowers HbA1c levels in patients with type 2 diabetes

Savient terminates Prosaptide development efforts

InterMune sells oritavancin rights to Targanta Therapeutics

Enrollment closes in PRECISE trial of cintredekin besudotox

Animal study begins for Acusolin for cataracts

ChimeriVax-West Nile vaccine enters phase II

Novartis seeks Japanese approval for Glivec in Ph+ ALL

Wyeth and Progenics collaborate on development of methylnaltrexone

Able Laboratories sells assets to Sun Pharmaceutical Industries

Synta outlines development priorities in 2006

Positive preliminary results from study of TRANSDUR-Sufentanil patch

Recent Pfizer patent discloses new anxiolytics

New beta-adrenoceptor antagonists for eye disorders reported by Othera

Novel therapeutic agents for respiratory disorders claimed in recent patents

Results of a phase III trial evaluating human papillomavirus vaccination with Gardasil

NDA submitted for protease inhibitor TMC-114

Revlimid receives FDA approval

Insights into Cdk1 inhibition and mitotic timing

Ranolazine improves exercise ability in diabetic angina patients

Benefit of eculizumab in paroxysmal nocturnal hemoglobinuria seen at 3 years

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...